Learning outcomes / Meeting objective
- Explore challenges to the implementation of dose-finding studies in oncology
- Discuss opportunities to improve dosing strategies given ongoing challenges
- Identify key considerations for selecting appropriate dose optimization strategies in oncology in light of FDA’s project OPTIMUS
- Potential implications of project OPTIMUS for dose-finding strategies in oncology early development in Europe and beyond
The target is a multidisciplinary audience of academia representatives, EU and US regulatory bodies (EMA, FDA, National Agencies), the pharmaceutical industry, HTAs, and patient advocates.